Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A

Anhui Wanbang Pharmaceutical Technology Co., Ltd. Class A

SSZSE:301520
51.41
CNY
-2.11
(-3.94%)
0.08EPS
1,695.70P/E
6.62BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.98
1.69
2.08
3.02
3.72
4.52
4.05
2.96
2.68
Basic EPS, GAAP
0.53
0.44
0.81
1.17
1.41
1.43
0.91
0.39
0.04
Free Cash Flow per Basic Share
0.48
0.23
0.6
0.57
0.31
-0.19
0.05
-0.29
- -
Dividend per Share
0.33
0.07
- -
- -
- -
- -
0.33
0.25
0.01
Book Value per Share
1.19
3.78
2.16
3.33
4.74
15.69
16.21
16.24
16.07
Tangible Book Value per Share
1.12
3.69
2.15
3.18
4.56
15.51
16.09
16.13
13.56
Basic Weighted Avg Shares
53
61
67
70
70
76
94
93
93
Sales/Revenue/Turnover
105
103
139
211
261
342
379
274
249
Operating Margin (%)
28.78
27.49
42.19
41.05
40
32.85
16.22
5.74
-2.33
Depreciation Expense
2
3
4
4
5
10
15
17
- -
Net Income, GAAP
28
27
55
82
99
108
86
36
4
Effective Tax Rate (%)
13.52
13.12
13.13
13.21
11.17
9.66
4.43
- -
- -
Profit Margin (%)
26.63
25.81
39.18
38.78
37.86
31.62
22.56
13.29
1.56
Working Capital
-8
25
120
182
221
1,295
1,328
1,295
1,066
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
1
Total Equity
17
53
151
233
332
1,464
1,513
1,515
1,533
Return on Invested Capital (%)
- -
60.23
49.99
39.13
33.6
12.02
5.61
- -
- -
Return on Capital (%)
- -
72.22
53.48
42.65
34.97
12.04
5.75
- -
- -
Return on Common Equity (%)
- -
76.48
53.48
42.65
34.98
12.04
5.75
2.41
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
39
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
93
93
93
Market Capitalization
2,803
3,028
6,620

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,351
1,337
1,205
Cash, Cash Equivalents & STI
1,141
1,068
936
Accounts Receivable, Net
70
96
101
Inventories
1
1
1
Total Current Liabilities
66
268
139
Payables & Accruals
- -
- -
- -
ST Debt
- -
39
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
88.32%
0.13%
Free Cash Flow
- -
-197.65%
-640.83%
Net Income, GAAP
- -
0.4%
-57.4%
Sales/Revenue/Turnover
- -
17.91%
-27.67%
Total Cash Common Dividend
- -
- -
-25.48%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
90
97
106
86
379
2025
71
76
- -
65
274
2026
31
57
96
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.32
0.27
0.24
0.08
0.91
2025
0.13
0.16
- -
0.04
0.39
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.33
2025
0.24
- -
- -
0.01
0.25
2026
- -
- -
- -
- -
- -

Company Description

CEO
Chun Lei Tao
Full Time Employees
376
Sector
Health technology
Industry
Biotechnology
Address
Hefei China
IPO Date
Sep 25, 2023
Website
ahwbyy.cn
Business
Anhui Wanbang Pharmaceutical Technology Co., Ltd. is a China-based contract research organization that provides comprehensive, one-stop research and development outsourcing services across the pharmaceutical product lifecycle. Founded in 2006 and headquartered in Hefei, Anhui Province, the company primarily serves pharmaceutical manufacturers, biotechnology enterprises, medical device developers, and scientific research institutions throughout mainland China. The company organizes its operations into clinical research services, pharmaceutical chemistry and formulation research, and technology transfer solutions. Its core offerings include bioequivalence and clinical pharmacology studies; Phase I through Phase III clinical trial design, site selection, and trial monitoring; Site Management Organization services; biological sample analysis and pharmacokinetics testing; clinical data management and biostatistical analysis; independent third-party clinical audits; generic drug research and consistency evaluation; formulation development, chemical synthesis, and analytical testing; as well as regulatory filing, drug registration dossier compilation, and technology transfer services. In recent strategic corporate developments, the company completed its initial public offering on the Shenzhen Stock Exchange ChiNext board in September 2023 under ticker 301520. In June 2026, the company completed the acquisition of a 75.52 percent controlling stake in Anhui Saidesheng Pharmaceutical Technology Co., Ltd. for approximately RMB 302 million to expand its full-chain clinical research capabilities in innovative drugs across oncology, respiratory, and gastroenterology indications, while incorporating specialized third-party auditing capabilities via Saidesheng subsidiary Beijing Dinghui Sichuang. The company has also continued to broaden its business scope beyond traditional generic drug bioequivalence into complex generics, biosimilars, medical device testing, and integrated healthcare technical services.